(Q54411632)

English

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

author name string

Deniz Tural

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

Sebnem Batur

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

Sibel Erdamar

3

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

Emre Akar

4

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

Nuray Kepil

5

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

Nil Molinas Mandel

6

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

Süheyla Serdengeçti

7

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

publication date

1 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

35

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

1041-1049

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

https://scigraph.springernature.com/pub.10.1007/s13277-013-1138-8

0 references

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

Chemotherapy for colorectal cancer liver metastases

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

PI3K expression and PIK3CA mutations are related to colorectal cancer metastases

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1138-8

21 January 2018

Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/23996432

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23996432

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13277-013-1138-8

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

release_pzvugx65unhljnwlu2nj5c6hdu

1 reference

https://api.fatcat.wiki/v0/release/pzvugx65unhljnwlu2nj5c6hdu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23996432

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54411632&oldid=1835437700"